NIOSH hazardous drugs list post-publication update adds three drugs to Table 1 via MSHI-based inclusion (July 17, 2025)

NIOSH updated the online update log for its "NIOSH List of Hazardous Drugs in Healthcare Settings, 2024" to state that certain drugs with manufacturer’s special handling information (MSHI) meeting the NIOSH definition should be treated as hazardous drugs and are considered included in Table 1. The July 17, 2025 update identifies datopotamab deruxtecan (Datroway®), treosulfan (Grafapex™), and telisotuzumab vedotin (Emrelis™) as included. This impacts healthcare and other employers’ hazardous drug handling programs (e.g., risk assessments, engineering controls, PPE, handling procedures) that rely on the NIOSH HD List.